Burns : journal of the International Society for Burn Injuries · 2025
Comparison of effect of Ringer's lactate and isotonic bicarbonate combination therapy with Ringer's lactate alone in early fluid resuscitation of burns patients - A randomised controlled trial.
СтатьяРандомизированное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Datchinamourthy Thamizharasan, Kumar Shailendra, Maitra Souvik, Bhattacharjee Sulagna, Patel Nishant, Kumar Rakesh, Ranganathan Poornima Diana, Kumar Amit, Kashyap Lokesh, Singhal Maneesh
Аннотация
BACKGROUND: Severe burns cause systemic inflammatory response, capillary leak, and profound metabolic acidosis from both lactic and non-lactic acid sources. Ringer's lactate (RL) remains the resuscitation standard but isotonic bicarbonate (IB, SID ≈ 150) provides superior alkalinizing capacity. This trial evaluated whether combining IB with RL in a 1:1 ratio improves perfusion compared to RL in early burn resuscitation.
METHODS: In this single-centre randomized controlled trial, 134 adult patients with ≥ 15 % TBSA burns presenting within 12 h were randomized to receive RL (2 ml/kg/%TBSA; n = 67) or IB+RL (1:1, 2 ml/kg/%TBSA; n = 67) guided by the modified Brooke formula. The primary outcome was 24-hour lactate reduction. Secondary outcomes included acid-base parameters, electrolytes, glucose-insulin profile, renal function, vasopressor use, SOFA scores, and 7-day mortality. Multiplicity correction was applied for secondary endpoints.
RESULTS: Median 24-hour lactate reduction was similar between RL [45.9 % (29.1-56.6)] and IB+RL [42.7 % (32.7-58.1); p = 0.752]. Conventional acid-base parameters were comparable, but IB+RL showed greater improvement in standard base excess (BE), alactic base excess (aBE), ΔaBE, ΔeSID, and ΔHCO₃⁻; only ΔHCO₃⁻ and ΔaBE retained borderline significance after multiplicity correction. Electrolyte trends included more hypokalemia and hypocalcemia in IB+RL. Glucose trended higher with IB+RL, but insulin requirements and osmolality remained similar. Fluid requirements, urine output, AKI incidence, vasopressor use, SOFA scores, and 7-day mortality were comparable.
CONCLUSION: Adding IB to RL did not improve perfusion but showed exploratory acid-base benefits without excess harm. Findings are hypothesis-generating and warrant validation in larger multicentre trials with individualized bicarbonate strategies.
METHODS: In this single-centre randomized controlled trial, 134 adult patients with ≥ 15 % TBSA burns presenting within 12 h were randomized to receive RL (2 ml/kg/%TBSA; n = 67) or IB+RL (1:1, 2 ml/kg/%TBSA; n = 67) guided by the modified Brooke formula. The primary outcome was 24-hour lactate reduction. Secondary outcomes included acid-base parameters, electrolytes, glucose-insulin profile, renal function, vasopressor use, SOFA scores, and 7-day mortality. Multiplicity correction was applied for secondary endpoints.
RESULTS: Median 24-hour lactate reduction was similar between RL [45.9 % (29.1-56.6)] and IB+RL [42.7 % (32.7-58.1); p = 0.752]. Conventional acid-base parameters were comparable, but IB+RL showed greater improvement in standard base excess (BE), alactic base excess (aBE), ΔaBE, ΔeSID, and ΔHCO₃⁻; only ΔHCO₃⁻ and ΔaBE retained borderline significance after multiplicity correction. Electrolyte trends included more hypokalemia and hypocalcemia in IB+RL. Glucose trended higher with IB+RL, but insulin requirements and osmolality remained similar. Fluid requirements, urine output, AKI incidence, vasopressor use, SOFA scores, and 7-day mortality were comparable.
CONCLUSION: Adding IB to RL did not improve perfusion but showed exploratory acid-base benefits without excess harm. Findings are hypothesis-generating and warrant validation in larger multicentre trials with individualized bicarbonate strategies.